De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
about
Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinomaManagement of recurrent hepatocellular carcinoma after liver transplantDiagnostic and therapeutic management of hepatocellular carcinoma2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinomaThe benefit of sirolimus maintenance immunosuppression and rabbit antithymocyte globulin induction in liver transplant recipients that develop acute kidney injury in the early postoperative periodMammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects.A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies.An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithmThe impact of sirolimus on hepatitis C recurrence after liver transplantation.Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.Liver transplantation for hepatocellular carcinoma: outcomes and treatment options for recurrence.Factors predicting survival after post-transplant hepatocellular carcinoma recurrenceSorafenib: where do we go from here?Hepatocellular carcinoma: defining the place of surgery in an era of organ shortage.mTOR inhibitors for hepatocellular cancer: a forward-moving target.mTOR inhibitor-associated dermatologic and mucosal problems.Immunosuppression and hepatocellular carcinoma.Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report.Current opinion on the role of resection and liver transplantation for hepatocellular cancer.Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this?Adverse events associated with mTOR inhibitors.Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma.Liver Transplantation for HCC: A Review.Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.Hepatocellular carcinoma: systemic therapies and future perspectives.Mammalian target of rapamycin inhibition in hepatocellular carcinoma.A retrospective 15-year review: survival advantage after switching to sirolimus in hepatitis C virus infected liver graft recipients.Liver transplantation as a management of hepatocellular carcinoma.What is the best immunosuppressant combination in terms of antitumor effect in hepatocellular carcinoma?mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.Additive effect of sirolimus and anti-death receptor 5 agonistic antibody against hepatocellular carcinoma.Trends in the use of maintenance immunosuppressive drugs among liver transplant recipients in Taiwan: a nationwide population-based study.Mediastinal mass diagnosed by endobronchial ultrasound as recurrent hepatocellular carcinoma in a post-liver transplantation patient.A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma.Overview of immunosuppression in liver transplantation.A Decade of Experience Using mTor Inhibitors in Liver Transplantation.Inhibition of mammalian target of rapamycin: the janus face of immunosuppression?
P2860
Q24635267-08324B72-E983-4E28-B490-8BDDC8234773Q26997063-60D95AC1-280D-4D0A-B258-3A3E4DA64CE0Q26999043-8312A602-0188-46D4-AE17-6C859295A9F2Q28392783-061A9639-8AA4-44B1-B7CA-B0F2E6F48284Q28394414-327229B4-9E52-4CB3-90CC-E802B00B9DDFQ30300206-FD91BFDB-4D76-4053-9F35-C6FE614AB8CAQ33393707-EA908D61-281E-4892-829F-32D27C2F4D63Q33575450-F709E2BF-9C3F-479C-8022-07B66A35ABC2Q34409128-CB47F73A-16E0-4235-8079-23B185ADFA92Q34417009-A1788138-A179-4987-8D84-CF0B4053A90AQ34522556-3102BA5B-196E-495E-91E9-0C729E03F24CQ34632966-1F6924F5-4A9E-4B61-A9CC-EFA9E9B14F8FQ35779474-6BE8CBE5-DF54-451F-9AD4-616A991B9121Q36662813-1EF79C14-6C98-46A6-A35E-E3420DAE34ABQ36708741-8E99F3F7-5950-4B1C-9FEB-62720AE7C751Q37235259-649D2EE3-4D32-4241-8C0B-41F5CC017881Q37385392-596FF14F-D86F-4DAB-B00C-58F0BCCA40A2Q37710669-F23DBC9A-3796-4B53-B5DE-BAEB65130E32Q37867072-F28A5F0E-17BB-42E7-812F-D70FFD80F9FEQ37952030-B2336BA3-7D3A-46D0-9728-AB32AF00D063Q38019845-07808F13-2DCE-4B5E-9FCA-4732CE70F939Q38045000-7C3EA3D5-E83F-4CC7-9A70-A91944EBA4CBQ38065315-34228AA3-19EB-4062-8BB8-3CEF12B59BD5Q38068519-BF8B8B9F-1364-481A-B38C-6963AB85283BQ38070693-8687AA39-2504-4700-910E-B1705931F28EQ38078347-6BF04090-F5B6-4913-A0C8-016717BBD582Q38221424-C881CA86-4F81-4489-A9BA-179BC155C925Q38246965-077FED4E-FED2-4B74-885B-83F1677C1CD4Q38271964-A2057CD1-1855-4E41-82CA-5597251972C2Q38286355-C3393117-AAD4-40DB-8B37-66726B7E5786Q38519906-3A8A950A-C70B-41D9-8BE3-F40677C3EDD0Q38837109-593DDB91-3CE7-42A7-8477-D244409FBA19Q38962103-0439EC15-E939-4F72-ACC1-D0D93F1A050DQ39118820-5DBD6DCF-026A-4E1E-AF47-60B6EE14D9B8Q40073855-12AFA5A4-F7E4-4FC3-945D-64BC311FD70AQ41884873-2A2AB1D3-E537-444D-A322-3C1864DDC7E0Q42064611-62A7E25D-6C4D-4CC1-BD3D-DFE121B6D4FAQ42555714-9A01CFB8-2A9F-453E-912F-CEC35DA65E51Q42704361-BBCA874F-A16D-4FDC-BC51-51628CBF2E2DQ43107477-D5A344BF-2F61-4663-BFFD-9BBB0FD742A3
P2860
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
De novo sirolimus-based immuno ...... erm outcomes and side effects.
@en
De novo sirolimus-based immuno ...... erm outcomes and side effects.
@nl
type
label
De novo sirolimus-based immuno ...... erm outcomes and side effects.
@en
De novo sirolimus-based immuno ...... erm outcomes and side effects.
@nl
prefLabel
De novo sirolimus-based immuno ...... erm outcomes and side effects.
@en
De novo sirolimus-based immuno ...... erm outcomes and side effects.
@nl
P2093
P1433
P1476
De novo sirolimus-based immuno ...... erm outcomes and side effects.
@en
P2093
A M James Shapiro
Christian Toso
David L Bigam
Glenda A Meeberg
Jose Oberholzer
Klaus Gutfreund
Norman M Kneteman
Vincent G Bain
Winnie W S Wong
P304
P356
10.1097/01.TP.0000262607.95372.E0
P577
2007-05-01T00:00:00Z